Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Neurol Neurosurg Psychiatry ; 85(1): 17-22, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23843542

RESUMO

OBJECTIVES: Levodopa and other dopaminergic treatments have not had the expected effect on survival in Parkinson's disease (PD). Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) has been shown to improve motor function, motor fluctuations, health-related quality of life, and to reduce medication usage and drug-induced dyskinesia in patients with severe PD refractory to medical therapy. Little however, has been described on the impact of STN-DBS on the survival of these patients. We aim in this study to examine the impact of STN-DBS on the survival of patients with severe PD. METHODS: Patients who were eligible for STN-DBS were given the choice of undergoing surgery or continuing on medical treatment. Those who exercised patient choice and preferred to continue with medical treatment formed a control population. All eligible patients seen in a 10-year period are included in this study. Our primary outcome measure is a difference in mortality between the two groups with a secondary measure of admission rates to residential (nursing home) care. RESULTS: 106 patients underwent STN-DBS, and 41 patients exercised patient choice and declined the procedure. The two groups were matched for age, gender, ethnicity, duration of disease, rates of pre-existing depression and Levodopa equivalent doses of anti-Parkinson's medications taken. Patients undergoing STN-DBS had significantly longer survival and were significantly less likely to be admitted to a residential care home than those managed purely medically. The statistical significance of these findings persisted after adjusting for potential confounding factors (survival: p=0.002, HR 0.29 (0.13 to 0.64) (residential care home admission: OR: 0.1 (95% CI 0.0 to 0.3; p<0.001). INTERPRETATION: We show for the first time that there is a survival advantage of DBS surgery in advanced PD. The effect of potential bias factors is examined. The survival advantage may arise for several postulated reasons, ranging from improvement in axial functions, such as swallowing, to some as yet unrecognised benefit of reduction in dopaminergic medication. These findings are of great interest to both patients with PD and the health professionals considering the treatment options for patients with severe PD.


Assuntos
Estimulação Encefálica Profunda/métodos , Doença de Parkinson/terapia , Idoso , Antiparkinsonianos/uso terapêutico , Causas de Morte , Depressão/etiologia , Depressão/psicologia , Feminino , Humanos , Estimativa de Kaplan-Meier , Levodopa/uso terapêutico , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Doença de Parkinson/mortalidade , Doença de Parkinson/psicologia , Escalas de Graduação Psiquiátrica , Análise de Regressão , Núcleo Subtalâmico/fisiologia , Sobrevida , Análise de Sobrevida , Resultado do Tratamento
2.
Br J Neurosurg ; 28(2): 199-203, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24053314

RESUMO

BACKGROUND. Chronic subdural haematoma (CSDH) is a common condition that increases in incidence with rising age. Evacuation of a CSDH is one of the commonest neurosurgical procedures; however the optimal peri-operative management, surgical technique, post-operative care and the role of adjuvant therapies remain controversial. AIM. We propose a prospective multi-centre audit in order to establish current practices, outcomes and national benchmarks for future studies. METHODS. Neurosurgical units (NSU) in the United Kingdom and Ireland will be invited to enrol patients to this audit. All adult patients aged 16 years and over with a primary or recurrent CSDH will be eligible for inclusion. OUTCOME MEASURES AND ANALYSIS. The proposed outcome measures are (1) clinical recurrence requiring re-operation within 60 days; (2) modified Rankin scale (mRS) score at discharge from NSU; (3) morbidity and mortality in the NSU; (4) destination at discharge from NSU and (5) length of stay in the NSU. Audit standards have been derived from published systematic reviews and a recent randomised trial. The proposed standards are clinical recurrence rate < 20%; unfavourable mRS (4-6) at discharge from NSU < 30%; mortality rate in NSU < 5%; morbidity rate in NSU < 10%. Data will be submitted directly into a secure online database and analysed by the study's management group. CONCLUSIONS. The audit will determine the contemporary management and outcomes of patients with CSDH in the United Kingdom and Ireland. It will inform national guidelines, clinical practice and future studies in order to improve the outcome of patients with CSDH.


Assuntos
Hematoma Subdural Crônico/cirurgia , Estudos Multicêntricos como Assunto/métodos , Procedimentos Neurocirúrgicos/métodos , Adolescente , Corticosteroides/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Benchmarking , Coleta de Dados , Interpretação Estatística de Dados , Drenagem , Feminino , Pesquisas sobre Atenção à Saúde , Humanos , Irlanda , Masculino , Pessoa de Meia-Idade , Neurocirurgia , Procedimentos Neurocirúrgicos/estatística & dados numéricos , Assistência Perioperatória , Cuidados Pós-Operatórios , Estudos Prospectivos , Resultado do Tratamento , Reino Unido , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA